Abstracts

ACCEPTABILITY AND FEASIBILITY OF A NEW URINE-BASED TENOFOVIR ADHERENCE TEST IN KENYA

Background: Objective measures of oral pre-exposure prophylaxis (PrEP) adherence – especially point-of-care (POC) measures that enable real-time assessment, intervention, and feedback – have the potential to improve adherence. Our team previously developed and validated a novel urine-based POC measure of PrEP adherence. In this study, we sought to determine whether this urine assay for real-time…

CYTOKINE PROFILE IN DIFFERENT POST-COVID-19 CONDITION PHENOTYPES

Background: At least 10% of SARS-CoV-2 infected patients suffer from persistent symptoms for >12 weeks, known as post-COVID-19 condition (PCC) or Long Covid. Reported symptomatology is diverse with >200 physical and neurological debilitating symptoms. Here, we analyzed pro-inflammatory cytokine levels as a potential mechanism underlying persistent symptomatology. Methods: Clinical data and samples used belong to…

HBV TRANSMISSION IN HOUSEHOLDS OF WOMEN ENGAGED IN DR CONGO’S HIV PMTCT PROGRAM

Background: Hepatitis B virus (HBV) remains endemic in Africa despite effective vaccines. Limited studies suggest horizontal modes of transmission within households or communities may be driving continued endemicity in the region. The relative impact of horizontal versus vertical transmission is unknown. Methods: We conducted the Horizontal and Vertical Transmission of Hepatitis B in the Democratic…

HEPATITIS C BURDEN IN GREECE, ITALY, PORTUGAL, AND SPAIN: 2000-2019

Background: Viral Hepatitis remains a health priority. We performed a comprehensive evaluation of epidemiological HCV estimates in Southern countries of Western Europe and assessed the impact of the 2008 economic crisis on HCV burden. Methods: We analyzed data of the Global Burden of Diseases to describe the patterns of six measures of HCV burden [prevalence,…

GERMLINE-TARGETING ENV TRIMER ELICITS bNAb PRECURSORS IN INFANT, NOT JUVENILE MONKEYS

Background: An HIV vaccine that induces protective, broadly-neutralizing antibodies (bnAbs) prior to sexual debut is critical to eliminate the ~410,000 new infections annually that occur among youth aged 15 to 24 years worldwide, and provide lifelong immunity. Recent work has established that HIV-infected children develop bnAbs earlier and at a higher frequency than adults, suggesting…

THIGH INJECTIONS OF CABOTEGRAVIR+RILPIVIRINE IN VIRALLY SUPPRESSED ADULTS WITH HIV-1

Background: Cabotegravir (CAB) + rilpivirine (RPV) long-acting (LA) administered via gluteal intramuscular (IM) injections is recommended by treatment guidelines for maintaining HIV-1 virologic suppression. Previous data in healthy participants receiving single CAB+RPV LA IM injections to the vastus lateralis (thigh muscle) were supportive of further evaluation. Here we present the results of a substudy evaluating…

ASSOCIATION OF HIV CONTROL AND IMMUNOSUPPRESSION WITH NADC RISK AMONG PATIENTS ON ART

Background: Since inception of highly active antiretroviral therapy in 1996, AIDS-related mortality has decreased, and life expectancy among people with HIV (PHIV) has increased. This has translated into an increased prevalence of age-related conditions including non-AIDS defining cancers (NADCs). Our study investigated the association of measures of immunosuppression and HIV control with NADCs with viral…

COSTS OF PROVIDING PHARMACY-INITIATED PrEP IN KENYA: FINDINGS FROM A PILOT STUDY

Background: Provision of oral HIV pre-exposure prophylaxis (PrEP) at pharmacies in high HIV prevalence settings can expand access to PrEP and increase convenience to clients; however, implementation costs are uncertain. We conducted activity-based microcosting to analyze costs associated with this novel PrEP delivery model within an ongoing pilot study evaluating pharmacy-based PrEP delivery in Kenya…